Merus N.V. (MRUS)
Listed on NASDAQ • Healthcare / Biotechnology
Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Explore More Data
Key Information
Symbol:
MRUS
CEO:
Sven Ante Lundberg
Exchange:
NASDAQ
CIK:
0001651311
Website:
https://www.merus.nl
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
95.18
Change
0.14
Change %
0.15%
Open
94.92
Previous Close
95.04
High
95.2
Low
94.92
Volume
499,593
Market Cap
7,218,886,656
EV/EBITDA
0
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
75,844,579
FloatShares
65,817,926
Float Ratio
86.78%
Shares Short
2,214,850
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
2.93%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
0.53 trading days
Held Percent Insiders
2.29%
Held Percent Institutions
101.28%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date (Estimated) | 2025-11-12 |
| Earnings Call (Estimated) | |
| Avg EPS Estimate | -0.9026 |
| Low EPS Estimate | -1.29 |
| High EPS Estimate | 0.449 |
| Revenue | |
| Avg Revenue Forecast | 9,213,570 |
| Low Revenue Forecast | 6,600,000 |
| High Revenue Forecast | 12,150,000 |
MRUS Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $635,932,032 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 7.588 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 7.972 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $12,317,000 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
MRUS Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $-368,772,000 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-317,267,008 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-174,430,496 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 36.99% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -794.06% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 0.00% | Net profit margin, which reflects overall profitability. |
MRUS Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 1.59% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $12,317,000 | Used together with cash and EBITDA to assess debt-paying ability. |
MRUS Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 3.20% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for MRUS (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $95.18 | Latest stock trading price |
| Price Target (High) | $97 | Analyst highest expected price |
| Price Target (Low) | $97 | Analyst lowest expected price |
| Price Target (Average) | $97 | Average target price across analysts |
| Price Target (Median) | $97 | Median of target prices |
| Average Rating Score | 2.75 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 13 | Number of analysts providing estimates |
| Cash Holdings | $635,932,032 | Total cash held by the company |
| Cash per Share | $8.38 | Cash value per outstanding share |
| Total Debt | $12,317,000 | Company's total debt |
| Quick Ratio | 7.588 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 7.972 | Overall short-term liquidity |
| Debt/Equity Ratio | 1.59% | Leverage ratio: Debt / Equity |
| EBITDA | $-368,772,000 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $56,606,000 | Total company revenue |
| Revenue per Share | $0.796 | Total revenue divided by shares outstanding |
| Gross Profit | 36.99% | Revenue minus cost of goods sold |
| Return on Assets | -26.53% | Net income / Total assets |
| Return on Equity | -51.57% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 3.20% | Year-over-year revenue growth |
| Gross Margin | 36.99% | Gross profit / Total revenue |
| EBITDA Margin | 0.00% | EBITDA / Revenue |
| Operating Margin | -794.06% | Operating income / Revenue |
| Profit Margin | 0.00% | Net income / Revenue |
| Free Cash Flow | $-174,430,496 | Cash left after capital expenditures |
| Operating Cash Flow | $-317,267,008 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |